Loading organizations...
Key people at Active Biotech Research AB.
Active Biotech Research AB is a clinical-stage biotechnology company based in Lund, Sweden, that develops small-molecule pharmaceuticals for the treatment of cancer and autoimmune diseases. The publicly traded firm focuses on advancing orally active immunomodulatory molecules, specifically leveraging its primary clinical assets, laquinimod and tasquinimod, to address unmet medical needs in oncology and immunology. Operating with a lean team of five full-time employees, the enterprise maintains a market capitalization of approximately 183.21 million SEK and reported a recent turnover of 7.28 million SEK. To advance its clinical pipeline and commercialization efforts, the company has historically established strategic development partnerships and out-licensing agreements with major pharmaceutical entities including Teva Pharmaceutical Industries, Ipsen, and NeoTX Therapeutics. Active Biotech Research AB was founded in 1998 as a corporate spin-off from the global pharmaceutical company Pharmacia and Upjohn.
Key people at Active Biotech Research AB.
Active Biotech AB is a Swedish biotechnology company focused on developing immunomodulatory pharmaceuticals for cancer and inflammatory eye diseases. It targets unmet medical needs with a portfolio including small molecules like Tasquinimod (Phase Ib/IIa for hematological cancers such as myelofibrosis and multiple myeloma) and Laquinimod (Phase I for non-infectious uveitis), plus Naptumomab (Phase Ib/II for solid tumors, partnered with NeoTX Therapeutics).[1][2][3][4] The company serves patients with severe conditions where the immune system plays a key role, solving problems like tumor-promoting signals in bone marrow and severe inflammatory eye disorders through orally active drugs and antibody-based immunotherapy, with a lean team of 6 employees driving clinical progress from Lund, Sweden.[1][2]
Active Biotech AB was originally incorporated in 1983 and re-formed in 1998 as a spin-off from Pharmacia & Upjohn, leveraging expertise in immune system-related drug development.[1][2] Headquartered in Lund, Sweden, it has evolved from broad pharmaceutical R&D to a specialized focus on cancer (hematological malignancies and solid tumors) and inflammatory eye diseases, building on core competencies in early-to-late stage clinical development.[2] Key leadership includes CEO Helen Tuvesson, guiding a small, experienced team through collaborations with institutions like Abramson Cancer Center, MD Anderson, and Stanford Medicine.[1]
Active Biotech rides the wave of immuno-oncology and inflammatory disease therapies, where modulating the immune system addresses unmet needs in hematological cancers and uveitis amid rising demand for targeted, orally administered treatments.[2][3][4] Timing aligns with advances in small-molecule immunomodulators and antibody-drug conjugates, fueled by market forces like aging populations driving cancer prevalence and gaps in eye inflammation therapies.[1][3] It influences Sweden's biotech ecosystem as a Lund-based innovator, contributing to Nasdaq Stockholm's life sciences cluster through spin-off heritage and global partnerships that validate immune-focused R&D.[1][2]
Active Biotech's path forward centers on advancing Tasquinimod to later-stage data in myelofibrosis/multiple myeloma, completing Laquinimod's biodistribution study for uveitis, and monitoring NeoTX's Naptumomab progress in solid tumors.[2][3][4] Trends like precision immuno-therapies and eye disease breakthroughs will shape its trajectory, potentially expanding partnerships or licensing for commercialization. Its influence may grow by delivering first-in-class options for niche indications, reinforcing its niche as an agile immunology specialist in biotech. This positions it to capitalize on immune-centric innovation, echoing its spin-off roots in high-need therapeutics.[1][2][4]
